Gillian Murphy

Group Leader

Research Group Home Page:: Murphy Group

Work address:: Cancer Research UK Cambridge Institute University of Cambridge Li Ka Shing Centre Robinson Way Cambridge CB2 0RE

Publications:: Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy.

E-pub date: 01 Jun 2014; Increased ERK signalling promotes inflammatory signalling in primary airway epithelial cells expressing Z α1-antitrypsin.

E-pub date: 15 Feb 2014; Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.

E-pub date: 31 Aug 2013; Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.

E-pub date: 31 Aug 2012; A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis.

E-pub date: 31 Aug 2012; Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1.

E-pub date: 31 Jul 2012; LPS activates ADAM9 dependent shedding of ACE from endothelial cells.

E-pub date: 27 Apr 2012; Lactoferricin mediates anabolic and anti-catabolic effects in the intervertebral disc.

E-pub date: 01 Apr 2012; Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex.

E-pub date: 01 Apr 2012; Membrane type 1 matrix metalloproteinase (MT1-MMP) ubiquitination at Lys581 increases cellular invasion through type I collagen.

E-pub date: 30 Mar 2012; Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain.

E-pub date: 01 Feb 2012; Tissue inhibitors of metalloproteinases.

E-pub date: 11 Nov 2011; Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness.

E-pub date: 01 Nov 2011; Modulation of integrin α4β1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration.

E-pub date: 31 Oct 2011; Mechanism of heparin acceleration of tissue inhibitor of metalloproteases-1 (TIMP-1) degradation by the human neutrophil elastase.

E-pub date: 31 Aug 2011; Biochemistry meets biology: key findings for bone calcification and a lifetime philosophy of collaboration.

E-pub date: 31 Aug 2011; Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes.

E-pub date: 11 Aug 2011; Two novel determinants of etoposide resistance in small cell lung cancer.

E-pub date: 15 Jul 2011; Cross-domain inhibition of TACE ectodomain.

E-pub date: 05 Apr 2011; Localizing matrix metalloproteinase activities in the pericellular environment.

E-pub date: 31 Jan 2011; MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src.

E-pub date: 01 Dec 2010; Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer.

E-pub date: 23 Nov 2010; Fell-Muir Lecture: Metalloproteinases: from demolition squad to master regulators.

E-pub date: 31 Aug 2010; Golgi reassembly stacking protein 55 interacts with membrane-type (MT) 1-matrix metalloprotease (MMP) and furin and plays a role in the activation of the MT1-MMP zymogen.

E-pub date: 31 Aug 2010; Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2).

E-pub date: 15 Aug 2010; Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA.

E-pub date: 31 Jul 2010; The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function.

E-pub date: 27 Jul 2010; Thiol isomerases negatively regulate the cellular shedding activity of ADAM17.

E-pub date: 27 May 2010; Role of the netrin-like domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity.

E-pub date: 21 May 2010; The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment.

E-pub date: 01 Apr 2010; Regulation of the proteolytic disintegrin metalloproteinases, the ‘Sheddases’.

E-pub date: 01 Apr 2009; Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein.

E-pub date: 31 Dec 2008; The ADAMs: signalling scissors in the tumour microenvironment.

E-pub date: 31 Dec 2008; Progress in matrix metalloproteinase research.

E-pub date: 31 Oct 2008; MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3.

E-pub date: 19 Aug 2008; The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma.

E-pub date: 01 Jun 2008; The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.

E-pub date: 15 Apr 2008; Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions.

E-pub date: 31 Mar 2008; Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?

E-pub date: 31 Mar 2008; Granulocyte-macrophage colony stimulating factor induces endothelial capillary formation through induction of membrane-type 1 matrix metalloproteinase expression in vitro.

E-pub date: 15 Mar 2008; Clipping, shedding and RIPping keep immunity on cue.

E-pub date: 01 Feb 2008; Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration.

E-pub date: 24 Aug 2007; TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4.

E-pub date: 20 Jul 2007; Membrane-type 1 matrix metalloproteinase stimulates cell migration through epidermal growth factor receptor transactivation.

E-pub date: 01 Jun 2007; Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration.

E-pub date: 25 May 2007; Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1.

E-pub date: 02 Mar 2007; Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli.

E-pub date: 01 Sep 2005; The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5′ bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1.

E-pub date: 01 Mar 2004; Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13.

E-pub date: 30 Nov 2002; Metalloproteinase inhibitors: biological actions and therapeutic opportunities.

E-pub date: 30 Sep 2002; The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs.

E-pub date: 30 Jun 2002; The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.

E-pub date: 30 Apr 2000; Localisation of matrix metalloproteinases and TIMP-2 in resorbing mouse bone.

E-pub date: 01 Mar 2000; Inhibition of the metalloproteinase domain of mouse TACE.

E-pub date: 31 May 1999; Evaluation of some newer matrix metalloproteinases.

E-pub date: 31 May 1999; TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.

E-pub date: 31 Aug 1998; Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3.

E-pub date: 31 Mar 1998; The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study.

E-pub date: 31 Dec 1997; MT1-MMP on the cell surface causes focal degradation of gelatin films.

E-pub date: 31 Dec 1997; Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases.

E-pub date: 30 Nov 1997; Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13).

E-pub date: 31 Aug 1997; Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens.

E-pub date: 31 Mar 1997; Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro.

E-pub date: 28 Feb 1997; The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction.

E-pub date: 28 Feb 1997; Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases.

E-pub date: 28 Feb 1997; Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis.

E-pub date: 28 Feb 1997; Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution.

E-pub date: 31 Jan 1997; The recognition sites of the integrins alpha1beta1 and alpha2beta1 within collagen IV are protected against gelatinase A attack in the native protein.

E-pub date: 31 Oct 1996; Chemically and conformationally authentic active domain of human tissue inhibitor of metalloproteinases-2 refolded from bacterial inclusion bodies.

E-pub date: 30 Sep 1996; Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases.

E-pub date: 31 Aug 1996; The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3.

E-pub date: 30 Jun 1996; Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme.

E-pub date: 30 Jun 1996; Metalloproteinase-mediated regulation of L-selectin levels on leucocytes.

E-pub date: 30 Apr 1996; Degradation of cartilage aggrecan by collagenase-3 (MMP-13).

E-pub date: 31 Jan 1996; Biochemical characterization of human collagenase-3.

E-pub date: 31 Dec 1995; The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function.

E-pub date: 31 Dec 1995; Activation of human neutrophil procollagenase by stromelysin 2.

E-pub date: 31 Dec 1995; Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes.

E-pub date: 30 Nov 1995; Gelatinase A possesses a beta-secretase-like activity in cleaving the amyloid protein precursor of Alzheimer’s disease.

E-pub date: 30 Nov 1995; Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities.

E-pub date: 31 Aug 1995; Evidence for the importance of weakly bound water for matrix metalloproteinase activity.

E-pub date: 31 Aug 1995; Gelatinases A and B.

E-pub date: 01 Aug 1995; Tissue inhibitors of matrix metalloendopeptidases.

E-pub date: 01 Aug 1995; Binding of gelatinases A and B to type-I collagen and other matrix components.

E-pub date: 30 Jun 1995; The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family.

E-pub date: 31 May 1995; Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases.

E-pub date: 31 Mar 1995; The second zinc atom in the matrix metalloproteinase catalytic domain is absent in the full-length enzymes: a possible role for the C-terminal domain.

E-pub date: 31 Dec 1994; Neutrophil collagenase (MMP-8) cleaves at the aggrecanase site E373-A374 in the interglobular domain of cartilage aggrecan.

E-pub date: 30 Nov 1994; Cell surface-mediated activation of progelatinase A: demonstration of the involvement of the C-terminal domain of progelatinase A in cell surface binding and activation of progelatinase A by primary fibroblasts.

E-pub date: 31 Oct 1994; Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family.

E-pub date: 30 Sep 1994; Regulation of matrix metalloproteinase activity.

E-pub date: 31 Aug 1994; The binding of gelatinases A and B to type I collagen yields both high and low affinity sites.

E-pub date: 31 Aug 1994; Neutrophil procollagenase can be activated by stromelysin-2.

E-pub date: 31 Aug 1994; Mutation of the active site glutamic acid of human gelatinase A: effects on latency, catalysis, and the binding of tissue inhibitor of metalloproteinases-1.

E-pub date: 30 Apr 1994; Proteolysis of human native and oxidised alpha 1-proteinase inhibitor by matrilysin and stromelysin.

E-pub date: 28 Feb 1994; Different domain interactions are involved in the binding of tissue inhibitors of metalloproteinases to stromelysin-1 and gelatinase A.

E-pub date: 28 Feb 1994; Metalloproteinase domain structure, cellular invasion and metastasis.

E-pub date: 01 Feb 1994; Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling.

E-pub date: 31 Oct 1993; Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain.

E-pub date: 30 Sep 1993; Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein.

E-pub date: 30 Sep 1993; Structural analysis of tissue inhibitor of metalloproteinases-1 (TIMP-1) by tryptic peptide mapping.

E-pub date: 31 May 1993; The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A.

E-pub date: 31 Mar 1993; Cell-mediated degradation of type IV collagen and gelatin films is dependent on the activation of matrix metalloproteinases.

E-pub date: 30 Nov 1992; The role of plasminogen activators in the regulation of connective tissue metalloproteinases.

E-pub date: 30 Nov 1992; Site-directed mutations that alter the inhibitory activity of the tissue inhibitor of metalloproteinases-1: importance of the N-terminal region between cysteine 3 and cysteine 13.

E-pub date: 30 Sep 1992; Biochemical characterization of matrilysin. Activation conforms to the stepwise mechanisms proposed for other matrix metalloproteinases.

E-pub date: 31 Aug 1992; The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases.

E-pub date: 30 Apr 1992; A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases.

E-pub date: 31 Dec 1991; Metalloproteinase digestion of cartilage proteoglycan. Pattern of cleavage by stromelysin and susceptibility to collagenase.

E-pub date: 31 Oct 1991; Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization.

E-pub date: 31 Aug 1991; The origin of matrix metalloproteinases and their familial relationships.

E-pub date: 31 Aug 1991; The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1.

E-pub date: 31 Jul 1991; The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity.

E-pub date: 31 Jul 1991; Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes.

E-pub date: 31 Jul 1991; Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP).

E-pub date: 30 Jun 1991; Isolation and characterisation of a chicken gelatinase (type IV collagenase).

E-pub date: 30 Jun 1991; Purification of recombinant human prostromelysin. Studies on heat activation to give high-Mr and low-Mr active forms, and a comparison of recombinant with natural stromelysin activities.

E-pub date: 30 Apr 1991; Proteolytic inactivation of human alpha 1 antitrypsin by human stromelysin.

E-pub date: 31 Jan 1991; Role and regulation of metalloproteinases in connective tissue turnover.

E-pub date: 01 Oct 1990; Metalloproteinases and cartilage proteoglycan depletion in chronic arthritis. Comparison of antigen-induced and polycation-induced arthritis.

E-pub date: 01 Feb 1990; Metalloproteinases and cancer invasion and metastasis.

E-pub date: 30 Sep 1989; Dissociation of tissue inhibitor of metalloproteinases (TIMP) from enzyme complexes yields fully active inhibitor.

E-pub date: 31 Jul 1989; Human and rat malignant-tumor-associated mRNAs encode stromelysin-like metalloproteinases.

E-pub date: 31 May 1989; Pump-1 cDNA codes for a protein with characteristics similar to those of classical collagenase family members.

E-pub date: 31 May 1989; Degradation of proteoglycan aggregate by a cartilage metalloproteinase. Evidence for the involvement of stromelysin in the generation of link protein heterogeneity in situ.

E-pub date: 31 Mar 1989; Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase.

E-pub date: 28 Feb 1989; Degradation of glomerular basement membrane by purified mammalian metalloproteinases.

E-pub date: 31 Aug 1988; Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes.

E-pub date: 31 Oct 1987; Comparison of human stromelysin and collagenase by cloning and sequence analysis.

E-pub date: 30 Nov 1986; Rapid purification of tissue inhibitor of metalloproteinases from human plasma and identification as a gamma-serum protein.

E-pub date: 31 Aug 1986; Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity.

E-pub date: 31 Oct 1985; Purification and characterization of a bone metalloproteinase that degrades gelatin and types IV and V collagen.

E-pub date: 31 Aug 1985; Tissue inhibitor of metalloproteinases. Identification of precursor forms synthesized by human fibroblasts in culture.

E-pub date: 31 Mar 1985; Metalloproteinase inhibitors from bovine cartilage and body fluids.

E-pub date: 31 Jan 1984; Effects of retinol and dexamethasone on cytokine-mediated control of metalloproteinases and their inhibitors by human articular chondrocytes and synovial cells in culture.

E-pub date: 31 Aug 1983; The interaction of purified rabbit bone collagenase with purified rabbit bone metalloproteinase inhibitor.

E-pub date: 30 Apr 1983; Purification and characterization of a rabbit bone metalloproteinase that degrades proteoglycan and other connective-tissue components.

E-pub date: 28 Feb 1983; Effects of products from macrophages, blood mononuclear cells and or retinol on collagenase secretion and collagen synthesis in chondrocyte culture.

E-pub date: 30 Jun 1982; Partial purification of collagenase and gelatinase from human polymorphonuclear leucocytes. Analysis of their actions on soluble and insoluble collagens.

E-pub date: 31 Mar 1982; Metalloproteinases from rabbit bone culture medium degrade types IV and V collagens, laminin and fibronectin.

E-pub date: 30 Nov 1981; Mammalian collagenases.

E-pub date: 01 Aug 1981; An inhibitor of collagenase from human amniotic fluid. Purification, characterization and action on metalloproteinases.

E-pub date: 31 Mar 1981; Purification of rabbit bone inhibitor of collagenase.

E-pub date: 31 Mar 1981; The latent collagenase and gelatinase of human polymorphonuclear neutrophil leucocytes.

E-pub date: 31 Oct 1980; Rabbit bone collagenase inhibitor blocks the activity of other neutral metalloproteinases.

E-pub date: 28 Feb 1979; Proteinase inhibitors of bovine nasal cartilage.

E-pub date: 28 Feb 1978; An inhibitor of mammalian collagenase from foetal rabbit bone in culture.

E-pub date: 01 Aug 1977; Collagenase activity from cultured non-gravid rabbit uterus.

E-pub date: 01 Aug 1977; A new factor that may control collagen resorption.

E-pub date: 31 Jul 1977; The detection and characterisation of collagenase inhibitors from rabbit tissues in culture.

E-pub date: 31 Jul 1977; Evidence that latent collagenases are enzyme-inhibitor complexes.

E-pub date: 30 Apr 1977; Collagenase is a component of the specific granules of human neutrophil leucocytes.

E-pub date: 31 Dec 1976; Show all Hide all

Gillian Murphy

Group Leader

Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy.

Increased ERK signalling promotes inflammatory signalling in primary airway epithelial cells expressing Z α1-antitrypsin.

Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice.

Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo.

A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis.

Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1.

LPS activates ADAM9 dependent shedding of ACE from endothelial cells.

Lactoferricin mediates anabolic and anti-catabolic effects in the intervertebral disc.

Pentosan polysulfate increases affinity between ADAMTS-5 and TIMP-3 through formation of an electrostatically driven trimolecular complex.

Membrane type 1 matrix metalloproteinase (MT1-MMP) ubiquitination at Lys581 increases cellular invasion through type I collagen.

Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain.

Tissue inhibitors of metalloproteinases.

Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness.

Modulation of integrin α4β1 by ADAM28 promotes lymphocyte adhesion and transendothelial migration.

Mechanism of heparin acceleration of tissue inhibitor of metalloproteases-1 (TIMP-1) degradation by the human neutrophil elastase.

Biochemistry meets biology: key findings for bone calcification and a lifetime philosophy of collaboration.

Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes.

Two novel determinants of etoposide resistance in small cell lung cancer.

Cross-domain inhibition of TACE ectodomain.

Localizing matrix metalloproteinase activities in the pericellular environment.

MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src.

Bcl-2 and β1-integrin predict survival in a tissue microarray of small cell lung cancer.

Fell-Muir Lecture: Metalloproteinases: from demolition squad to master regulators.

Golgi reassembly stacking protein 55 interacts with membrane-type (MT) 1-matrix metalloprotease (MMP) and furin and plays a role in the activation of the MT1-MMP zymogen.

Selective inhibition of ADAM12 catalytic activity through engineering of tissue inhibitor of metalloproteinase 2 (TIMP-2).

Tissue banking of diagnostic lung cancer biopsies for extraction of high quality RNA.

The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function.

Thiol isomerases negatively regulate the cellular shedding activity of ADAM17.

Role of the netrin-like domain of procollagen C-proteinase enhancer-1 in the control of metalloproteinase activity.

The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment.

Regulation of the proteolytic disintegrin metalloproteinases, the ‘Sheddases’.

Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein.

The ADAMs: signalling scissors in the tumour microenvironment.

Progress in matrix metalloproteinase research.

MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3.

The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma.

The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition.

Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions.

Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?

Granulocyte-macrophage colony stimulating factor induces endothelial capillary formation through induction of membrane-type 1 matrix metalloproteinase expression in vitro.

Clipping, shedding and RIPping keep immunity on cue.

Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration.

TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4.

Membrane-type 1 matrix metalloproteinase stimulates cell migration through epidermal growth factor receptor transactivation.

Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration.

Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1.

Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli.

The scl +18/19 stem cell enhancer is not required for hematopoiesis: identification of a 5′ bifunctional hematopoietic-endothelial enhancer bound by Fli-1 and Elf-1.

Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13.

Metalloproteinase inhibitors: biological actions and therapeutic opportunities.

The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs.

The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3.

Localisation of matrix metalloproteinases and TIMP-2 in resorbing mouse bone.

Inhibition of the metalloproteinase domain of mouse TACE.

Evaluation of some newer matrix metalloproteinases.

TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3.

Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3.

The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study.

MT1-MMP on the cell surface causes focal degradation of gelatin films.

Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases.

Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13).

Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens.

Matrix metalloproteinases MMP2 and MMP9 are produced in early stages of kidney morphogenesis but only MMP9 is required for renal organogenesis in vitro.

The role of the C-terminal domain of human collagenase-3 (MMP-13) in the activation of procollagenase-3, substrate specificity, and tissue inhibitor of metalloproteinase interaction.

Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases.

Analysis of the contribution of the hinge region of human neutrophil collagenase (HNC, MMP-8) to stability and collagenolytic activity by alanine scanning mutagenesis.

Identification and characterization of a novel human matrix metalloproteinase with unique structural characteristics, chromosomal location, and tissue distribution.

The recognition sites of the integrins alpha1beta1 and alpha2beta1 within collagen IV are protected against gelatinase A attack in the native protein.

Chemically and conformationally authentic active domain of human tissue inhibitor of metalloproteinases-2 refolded from bacterial inclusion bodies.

Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases.

The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation. Regulation by TIMP-2 and TIMP-3.

Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme.

Metalloproteinase-mediated regulation of L-selectin levels on leucocytes.

Degradation of cartilage aggrecan by collagenase-3 (MMP-13).

Biochemical characterization of human collagenase-3.

The C-terminal (haemopexin-like) domain structure of human gelatinase A (MMP2): structural implications for its function.

Activation of human neutrophil procollagenase by stromelysin 2.

Intermolecular autolytic cleavage can contribute to the activation of progelatinase A by cell membranes.